Free shipping on all orders over $ 500

Nocodazole

Cat. No. M3194

All AbMole products are for research use only, cannot be used for human consumption.

Nocodazole Structure
Synonym:

Oncodazole;R17934

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 33  USD33 In stock
10mg USD 54  USD54 In stock
50mg USD 200  USD200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Nocodazole is an anti-microtubule agent for ABL, ABL (E255K) and ABL (T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. Nocodazole is a high-affinity ligand for the cancer-related kinases including ABL phosphorylated, c-KIT, BRAF, and MEK with Kd of 0.091 μM, 1.6 μM, 1.8 μM and 1.6 μM, respectively. In addition, the Kd of Nocodazole for ABL (E255K) phosphorylated, ABL (T315I) phosphorylated, BRAF (V600E) and PI3Kγ is 0.12 μM, 0.17 μM, 1.1 μM and 1.5 μM, respectively. Nocodazole induces apoptosis in chronic lymphocytic leukemia cells. Nocodazole inhibits insulin-stimulated glucose transport. Nocodazole decreases apoptosis in some human colon carcinoma cells. Nocodazole impairs the morphology and directionality of migrating medial gan-glionic eminence cells. At high concentrations, nocodazole rapidly depolymerizes microtubules in cells, while low concentrations of nocodazole inhibit microtubule dynamic instability. Mitotic cells incubated with different concentrations of paclitaxel are inhibited from progressing to G1 phase 6 hours after release from the nocodazole block, with a median inhibitory concentration of 4 nM. Nocodazole-pretreated cells exposed to paclitaxel in the absence of nocodazole only form free-floating microtubules, whereas pretreated cells exposed to paclitaxel in the presence of nocodazole-assembled centrosome organize microtubules. Nocodazole disrupts microtubules by binding to β-tubulin. Nocodazole prevents the formation of one of the two interchain disulfide linkages. Nocodazole impairs the transport of vesicles. Nocodazole suppress METH-induced cell death and lysosomal dysfunction. METH-induced cell death is significantly decreased by Nocodazole pretreatment in comparison to METH alone. The tumor volume and tumor weight of the mice treated with Ketoconazole  plus  Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole  plus  Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole  or  Nocodazole alone. The tumor volume and tumor weight of the mice treated with Ketoconazole  plus  Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole  plus  Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole  or  Nocodazole alone.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Nude mice with COLO-205 tumor xenografts
Formulation 0.05% dimethyls
Dosages 5 mg/kg
Administration Administered via i.p.
Chemical Information
Molecular Weight 301.32
Formula C14H11N3O3S
CAS Number 31430-18-9
Solubility (25°C) DMSO 12 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Arif A Surani, et al. Optimizing Cell Synchronization Using Nocodazole or Double Thymidine Block

[2] S M Attia, et al. Dominant lethal effects of nocodazole in germ cells of male mice

[3] Hoi Tang Ma, et al. Synchronization of HeLa cells

[4] Kingo Endo, et al. Nocodazole induces mitotic cell death with apoptotic-like features in Saccharomyces cerevisiae

[5] Stephen Cooper, et al. Nocodazole does not synchronize cells: implications for cell-cycle control and whole-culture synchronization

Related Src-bcr-Abl Products
SI-2 hydrochloride

SI-2 hydrochloride is a highly promising SRC-3 inhibitor (PPI) with acceptable oral availability, with IC50 values of 3-20 nM for breast cancer cell death.

KB SRC 4 

KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.

Hydroxymethyl dasatinib 

Hydroxymethyl dasatinib (M24), a benzylhydroxy metabolite of Dasatinib, exhibits an IC50 of 46.7nM in K562 CML cells.

Asciminib hydrochloride

Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

Osteogenic Growth Peptide (10-14)

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Nocodazole, Oncodazole;R17934 supplier, Src-bcr-Abl, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.